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second reviewer was up to 3% more sensitive than the ﬁrst. In the
ovarian cancer, anti-infectives, hyperlipidemia, and clinical
breast cancer reviews, the second reviewer was up to 2% more
speciﬁc than the ﬁrst; all were signiﬁcant differences apart from
the clinical breast cancer review. In the cases where the second
reviewer was less sensitive or speciﬁc than the ﬁrst, these differ-
ences were non-signiﬁcant. CONCLUSIONS: While ﬁrst and
second reviewers tend to have similar sensitivity in including
citations, second reviewers tend to be more accurate at excluding
citations. This may be explained by the fact that, since more
caution is exercised in excluding citations than including them,
reviewers may wait until they have gained sufﬁcient experience to
make this decision.
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OBJECTIVES: To determine 12-months administrative preva-
lence rate of tic disorders (TD) and Tourette syndrome (TS), as
well as their coexistence with ADHD in a large German commu-
nity sample, against the background of the clinical importance of
this association. METHODS: Data for patients with a diagnosis
of any tic disorder (F95, ICD-10), Tourette disorder (F95.2), or
ADHD (F90.0 and/or F90.1) were extracted from the Nord-
baden claims database, covering the complete subpopulation
insured by Statutory Health Insurance (2.238 million lives in
2003; for comparison: total German population insured by SHI
in 2003, 70.2 million) in Nordbaden in South-Western Germany
(representing 82% of the total regional population). RESULTS:
A total of 3,618 patients with a diagnosis of any TD (hereof, 215
with TS) and 11,875 patients with ADHD were identiﬁed, cor-
responding to overall administrative prevalence rates (across all
age groups) of 0.16% (TD), 0.01% (TS), and 0.53% (ADHD).
Males were generally more often afﬂicted with any of the disor-
ders analyzed than females (TD, 0.19% versus 0.13% for
females; TS, 0.02% versus 0.01%; ADHD, 0.83% versus
0.27%). TD and TS were most prevalent among children 7–12
years (0.79% and 0.04%, respectively), and were signiﬁcantly
associated with presence of ADHD. ADHD was reported in
11.2% of children age 12 years with TD (boys, 15.4%; girls,
4.5%), compared to 3.1% (boys, 4.4%; girls, 1.7%) in the
community covered. Among adolescents (age 13–18 years), a
diagnosis of ADHD was tenfold more likely in patients with TD
(15.1%; boys, 18.5%; girls, 7.7%) compared with the commu-
nity group (1.5%; boys, 2.3%; girls, 0.7%). CONCLUSIONS:
These data extend the epidemiological database by providing for
the ﬁrst time information from Germany on the administrative
prevalence of TD, TS, and ADHD, as well as their coexistence,
hereby highlighting the relevance of taking comorbidity into
account when designing health care utilization and burden of
disease studies.
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OBJECTIVES: The majority (50–80%) of patients with general-
ized anxiety disorder (GAD) suffer from a variety of sleep prob-
lems. The objective of this study was to measure the direct effect
of anxiolytic treatment and, separately, its indirect effect medi-
ated by anxiety symptoms on sleep disturbance in patients with
GAD. METHODS: Data were obtained from an 8-week, double-
blind, randomized, ﬂexible-dose, placebo- and active-control
study in 372 GAD patients. Patients were assigned to pre-
gabalin (300–600 mg/day), venlafaxine XR (75–225 mg/day),
or placebo. Anxiety symptoms were measured by clinician-
administered HAM-A scale at baseline and on weeks 1–4, 6, and
8 and sleep disturbances were measured using the 4-item sleep
disturbance subscale on Medical Outcomes Study Sleep Scale
(MOS-SS), a validated patient-reported outcome measure. Statis-
tical mediation modeling was used to estimate the direct effects of
pregabalin and venlafaxine XR (relative to placebo) and the
indirect effects via anxiety symptoms, the mediator variable, as
measured by HAM-A total score. All available data from the trial
were used in the statistical analyses. RESULTS: Patients were
predominantly female (61%) and had a mean age of 41 years.
Path coefﬁcients for direct and indirect (mediated) paths for
patients in the pregabalin group indicated less sleep disturbance
with treatment. Fifty-three percent of the reduction in sleep dis-
turbance was due to the direct effect of pregabalin (p = 0.007).
The remainder of the reduction in sleep disturbance (47%, p =
0.015) was mediated via anxiety symptoms. In contrast, there
was no difference in sleep disturbance (p = 0.58) between patients
treated with venlafaxine XR or placebo. CONCLUSIONS: The
underlying relationships between treatment, anxiety symptoms,
and sleep disturbance are explicitly described and partitioned
through mediation modeling. About half of the total improve-
ment in sleep disturbance was identiﬁed as being due to the
direct effect of pregabalin independent of an effect on anxiety
symptoms.
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OBJECTIVES: To evaluate preliminary treatment outcomes of
Russian patients enrolled in the electronic-Schizophrenia Treat-
ment Adherence Registry (e-STAR) followed up for three months
after initiating treatment with risperidone long-acting injectable
(RLAI). METHODS: e-STAR is an international, prospective,
observational study of schizophrenia patients initiated on RLAI.
Psychiatric hospitalisations and medication use are collected ret-
rospectively for one year and prospectively every three months
for two years. Clinical and functioning outcomes, which are
measured by the Clinical Global Impression Severity (CGI-S)
Scale and the Global Assessment of Functioning (GAF) Scale,
respectively, are assessed prospectively every three months for
two years. McNemar’s test and paired-t test were used to evalu-
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